Neuropathix is a biopharmaceutical company focused on the research and development of a pipeline of next generation breakthrough therapeutics targeting inflammation to treat patients with significant unmet medical needs.
For almost a decade, Neuropathix has been a leader in the research, development and discovery of patented novel monotherapeutic agents for targeted drug candidates to treat Chemotherapy Induced Peripheral Neuropathy (CIPN), Hepatic Encephalopathy (HE), Mild Traumatic Brain Injury (mTBI) and chronic pain management. Neuropathix has advanced the development of a patented product platform of innovative Cannabinoid-inspired molecules for patients with these diseases and other significant medical needs. We have taken a science based, data-driven, validated approach to the discovery and development of novel and promising therapeutic molecules.
Our subsidiary Kannalife Sciences is the only company in the cannabinoid therapeutics arena to have licensed the U.S. Government Patent 6,630,507 – “Cannabinoids as Antioxidants and Neuroprotectants”. Our pre-clinical research on cannabidiol (CBD) and understanding of certain mechanism of action, its potential and its limitations, has resulted in our own target drug candidate discovery aimed at improving CBD’s pharmacokinetic and pharmacodynamic (“PK/PD”) aptitude.
In the discovery of KLS-13019 and other patented Cannabinoid-inspired New Chemical Entities (NCE’s), we have made significant improvements in the chemistry efficacy and safety of CBD-like molecules that are up to 200X more potent, 10X more bioavailable, 5X safer and 1000 times more effective than CBD.
